Mira-55 shows no cannabinoid-like CNS side effects in preclinical studies; advancing toward IND for inflammatory pain

MIRA PHARMACEUTICALS, INC.

Mira-55 tested at 10, 30, and 100 mg/kg in CNS assays; no psychogenic, motor, or anxiogenic effects observed.
No catalepsy or sedation; dose-dependent increase in time spent in open arms of Elevated Plus Maze (anxiety reduction).
Rimonabant (positive control) showed anxiety-like behavior, validating assay sensitivity.
Prior data demonstrated Mira-55 produced morphine-comparable analgesia in inflammatory pain model without opioid risks.
Company plans IND submission for inflammatory pain; additional preclinical studies ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.